USG Abdomen & Pelvis Report Analysis

Normal Findings (Incidental / Reassuring)

Significant / Abnormal Findings

1. Urinary Bladder - Internal Echoes

• The bladder is well distended but shows few internal echoes
• No calculus seen; wall is smooth
• What this means: Internal echoes in a non-calculus bladder typically suggest debris, which can be from:
  • Urinary tract infection (UTI) - most common cause (pyuria/cellular debris)
  • Hemorrhagic cystitis
  • Proteinuria/sediment
  • Rarely - small clot or early cystitis
• The report recommends urine examination - this is appropriate. A urine routine/microscopy and culture-sensitivity is the correct next step.

2. Uterus

• Anteverted - normal position
• Size: 6.1 x 3.6 x 2.9 cm - within normal limits for a reproductive-age woman
• No myometrial mass - no fibroids
• Fundal Endometrial Thickness (ET): 12.4 mm
  • In a woman with irregular menses (complaint noted: "C/o irregular menses"), an ET of 12.4 mm may be slightly on the higher side depending on cycle phase. In the secretory phase, up to ~16 mm is acceptable, but in the context of PCOS and anovulation, a thickened endometrium warrants monitoring because chronic anovulation leads to unopposed estrogen stimulation, increasing risk of endometrial hyperplasia.

3. Ovaries - Key Finding for PCOS

Conclusion: Possibility of PCOS - What Does This Mean?

Rotterdam Criteria (2003, updated 2023 international guidelines)

1. Irregular/oligomenorrhea or anovulation - ✅ Present (patient complaint of irregular menses)
2. Clinical or biochemical hyperandrogenism (elevated testosterone, hirsutism, acne, male-pattern hair loss) - Not assessed by USG - needs clinical + lab evaluation
3. Polycystic ovarian morphology on ultrasound (≥20 antral follicles OR ovarian volume ≥10 mL in at least one ovary) OR elevated AMH - ✅ Present (both ovaries >10 mL with multiple follicles)

The 2023 updated criteria (Harrison's 22E) require ≥20 antral follicles for the follicle count criterion (updated from the older ≥12 threshold), and ovarian volume ≥10 mL. This patient meets the volume criterion bilaterally.

Recommended Next Steps (Based on Guidelines)

1. Urine Routine & Microscopy + Culture (for the bladder echoes - to rule out UTI)
2. Hormonal Blood Tests:
   • Total & free Testosterone (for hyperandrogenism)
   • LH / FSH ratio (elevated LH in lean PCOS, but not a standalone criterion)
   • AMH (Anti-Müllerian Hormone) - elevated in PCOS, now part of 2023 criteria
   • Prolactin (to rule out hyperprolactinemia)
   • TSH (to rule out thyroid dysfunction)
   • Fasting insulin, fasting glucose, HbA1c (insulin resistance is very common)
3. Exclude other causes of irregular menses:
   • Congenital Adrenal Hyperplasia (CAH) - check 17-OHP
   • Cushing syndrome (if features present)
   • Androgen-secreting tumor (unlikely given bilateral findings without adnexal mass)

Summary for the Patient

• Most of the scan is completely normal - liver, kidneys, spleen, gallbladder, bowel, pelvis (no cysts, no masses, no fluid)
• The scan suggests PCOS is likely, based on the ovarian appearance and irregular periods together
• Some debris/echoes in the bladder were seen - a simple urine test will clarify if there is an infection
• The endometrial lining (12.4 mm) should be monitored - with irregular cycles and PCOS, the uterine lining can sometimes thicken; a gynaecologist should review this
• PCOS is a manageable condition - treatment is tailored to symptoms (cycle regulation, fertility, metabolic health) and typically starts with lifestyle changes and hormonal contraceptives if pregnancy is not being planned

• Berek & Novak's Gynecology, p. 1919-1920
• Harrison's Principles of Internal Medicine 22E, p. 3135

Recent PCOS/PMOS Management Guidelines: 2024-2026 Update

🔔 Major Breaking News: PCOS Has Been Renamed PMOS (May 2026)

Polyendocrine Metabolic Ovarian Syndrome (PMOS)

• "Polycystic" was inaccurate - many patients have no ovarian cysts
• The old name obscured the condition's core hormonal and metabolic drivers
• It caused delayed diagnosis, stigma, and fragmented care

The Current Gold Standard: 2023 International Evidence-Based Guideline

Management Framework (2023 Guideline, Applied in 2024-2025)

Step 1: Lifestyle - First Line for All Women

• Diet: Balanced, low-calorie; 45-65% carbohydrates, <30% fat, 20-35g/day fiber
• Exercise: 150-300 min/week moderate-intensity aerobic activity + muscle strengthening 2x/week
• Psychological support: Screen for depression, anxiety, and disordered eating at every visit
• Even modest weight loss (5-10%) significantly improves menstrual regularity, ovulation, and androgen levels

Step 2: Pharmacological Management by Goal

1. Letrozole (aromatase inhibitor) - First-line ovulation induction; superior to clomiphene for live birth rates
2. Clomiphene citrate - Alternative, but now second-line to letrozole
3. Metformin + letrozole/clomiphene - Combination improves ovulation and pregnancy rates
4. Gonadotropins (FSH/LH) - Second-line; risk of ovarian hyperstimulation syndrome (OHSS)
5. Laparoscopic Ovarian Drilling (LOD) - Surgical option for medication-resistant anovulatory infertility
6. IVF - Third-line when other options fail

• Screen all women at diagnosis: fasting glucose, HbA1c, fasting lipids, blood pressure
• GLP-1 receptor agonists (e.g., semaglutide, liraglutide): A 2024 meta-analysis (PMID: 39178623) confirms GLP-1 agonists significantly reduce weight, testosterone, and improve insulin resistance in PCOS with obesity. Now an emerging treatment option, especially in obesity-associated PCOS
• Statins: For dyslipidaemia when lifestyle fails
• Metformin: Continued emphasis for insulin-resistant, pre-diabetic patients

Key Cardiovascular Risk Update (2024)

• Blood pressure monitoring
• Lipid profile
• Fasting glucose / HbA1c
• BMI and waist circumference at every visit

Relevance to Your Scan

1. Confirm diagnosis with hormonal workup (testosterone, AMH, LH/FSH, prolactin, TSH)
2. Endometrial thickness 12.4 mm with anovulation - start COCP to protect against endometrial hyperplasia
3. Metabolic screening - HbA1c, fasting glucose, lipids
4. Lifestyle counselling as the foundation of management
5. No immediate fertility treatment needed unless she desires conception - in that case, letrozole is first-line

The condition is now formally called PMOS in the latest international literature, though "PCOS" will remain widely used clinically during the transition period.